EcoDrugPlus

Gastric Inhibitory Polypeptide Receptor

Ensembl ID : ENSMLUG00000001295
Gene Symbol: GIPR
2 Cross references
93 Possible Orthologues:

Glucagon Like Peptide 1 Receptor

Ensembl ID : ENSMLUG00000008008
Gene Symbol: GLP1R
2 Cross references
133 Possible Orthologues:

Glucagon Like Peptide 2 Receptor

Ensembl ID : ENSMLUG00000008663
Gene Symbol: GLP2R
4 Cross references
205 Possible Orthologues:

Glucokinase

Ensembl ID : ENSMLUG00000012016
Gene Symbol: GCK
2 Cross references
211 Possible Orthologues:

Glucosylceramidase Beta 1

Ensembl ID : ENSMLUG00000013382
Gene Symbol: GBA1
2 Cross references
254 Possible Orthologues:

Glutamate Ionotropic Receptor Ampa Type Subunit 1

Ensembl ID : ENSMLUG00000002344
Gene Symbol: GRIA1
2 Cross references
323 Possible Orthologues:

Glutamate Ionotropic Receptor Ampa Type Subunit 2

Ensembl ID : ENSMLUG00000017603
Gene Symbol: GRIA2
2 Cross references
321 Possible Orthologues:

Glutamate Ionotropic Receptor Ampa Type Subunit 3

Ensembl ID : ENSMLUG00000007407
Gene Symbol: GRIA3
2 Cross references
318 Possible Orthologues:

Glutamate Ionotropic Receptor Ampa Type Subunit 4

Ensembl ID : ENSMLUG00000005528
Gene Symbol: GRIA4
2 Cross references
324 Possible Orthologues:

Glutamate Ionotropic Receptor Nmda Type Subunit 2a

Ensembl ID : ENSMLUG00000015595
Gene Symbol: GRIN2A
2 Cross references
227 Possible Orthologues:

Glutamate Ionotropic Receptor Nmda Type Subunit 2b

Ensembl ID : ENSMLUG00000009625
Gene Symbol: GRIN2B
2 Cross references
330 Possible Orthologues:

Glutamate Ionotropic Receptor Nmda Type Subunit 3a

Ensembl ID : ENSMLUG00000006044
Gene Symbol: GRIN3A
4 Cross references
245 Possible Orthologues:

Select Keywords:


PREMIER has received funding from the Innovative Medicines Initiative 2 Joint Undertaking (JU) under grant agreement No 875508. The JU receives support from the EU’s Horizon 2020 research and innovation programme and the European Federation of Pharmaceutical Industries and Associations (EFPIA). The views reflect only the authors’ perspective and the JU is not responsible for any use that may be made of the information this manuscript contains. Elements of the website have been developed under projects from the Biocenter Finland Drug Discovery and Chemical Biology network. CSC-IT is thanked for providing computational resources. Content of the website is provided without guarantee for correctness. Data has been collected and integrated from multiple public sources, for the largest: FDA, HUGO Gene Nomenclature Committee, ChEMBL, IUPHAR/BPS guide to pharmacology, Reactome, UniProt, and Ensembl. Credit is given to Ensembl for collecting species images (provided under public domain licences such as Wikimedia and NHGRI).

PREMIER has received funding from the Innovative Medicines Initiative 2 Joint Undertaking (JU) under grant agreement No 875508. The JU receives support from the EU’s Horizon 2020 research and innovation programme and the European Federation of Pharmaceutical Industries and Associations (EFPIA). The views reflect only the authors’ perspective and the JU is not responsible for any use that may be made of the information this manuscript contains.

Elements of the website have been developed under projects from the Biocenter Finland Drug Discovery and Chemical Biology network. CSC-IT is thanked for providing computational resources. Content of the website is provided without guarantee for correctness. Data has been collected and integrated from multiple public sources, for the largest: FDA, HUGO Gene Nomenclature Committee, ChEMBL, IUPHAR/BPS guide to pharmacology, Reactome, UniProt, and Ensembl. Credit is given to Ensembl for collecting species images (provided under public domain licences such as Wikimedia and NHGRI).